These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 18316739)

  • 21. Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment.
    Hoffman-Luca CG; Yang CY; Lu J; Ziazadeh D; McEachern D; Debussche L; Wang S
    PLoS One; 2015; 10(6):e0128807. PubMed ID: 26070072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
    J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
    Bill KL; Garnett J; Meaux I; Ma X; Creighton CJ; Bolshakov S; Barriere C; Debussche L; Lazar AJ; Prudner BC; Casadei L; Braggio D; Lopez G; Zewdu A; Bid H; Lev D; Pollock RE
    Clin Cancer Res; 2016 Mar; 22(5):1150-60. PubMed ID: 26475335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53.
    Tian X; Dai S; Sun J; Jiang S; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Su J; Jiang Y
    Cell Physiol Biochem; 2016; 39(5):2088-2098. PubMed ID: 27825169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma.
    Andrews A; Warner K; Rodriguez-Ramirez C; Pearson AT; Nör F; Zhang Z; Kerk S; Kulkarni A; Helman JI; Brenner JC; Wicha MS; Wang S; Nör JE
    Clin Cancer Res; 2019 Mar; 25(5):1588-1600. PubMed ID: 30498096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function.
    Azmi AS; Aboukameel A; Banerjee S; Wang Z; Mohammad M; Wu J; Wang S; Yang D; Philip PA; Sarkar FH; Mohammad RM
    Eur J Cancer; 2010 Apr; 46(6):1122-31. PubMed ID: 20156675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
    Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
    Bioorg Chem; 2021 Dec; 117():105427. PubMed ID: 34794098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas.
    Nör F; Warner KA; Zhang Z; Acasigua GA; Pearson AT; Kerk SA; Helman JI; Sant'Ana Filho M; Wang S; Nör JE
    Clin Cancer Res; 2017 Feb; 23(4):1036-1048. PubMed ID: 27550999
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of MDM2 inhibitor MI-219 against lung cancer cells alone or in combination with MDM2 knockdown, a XIAP inhibitor or etoposide.
    Zheng M; Yang J; Xu X; Sebolt JT; Wang S; Sun Y
    Anticancer Res; 2010 Sep; 30(9):3321-31. PubMed ID: 20944104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors.
    Ji C; Wang S; Chen S; He S; Jiang Y; Miao Z; Li J; Sheng C
    Bioorg Med Chem; 2017 Oct; 25(20):5268-5277. PubMed ID: 28797774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
    Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
    Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents.
    Kumar A; Gupta G; Bishnoi AK; Saxena R; Saini KS; Konwar R; Kumar S; Dwivedi A
    Bioorg Med Chem; 2015 Feb; 23(4):839-48. PubMed ID: 25618595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells.
    Samudio IJ; Duvvuri S; Clise-Dwyer K; Watt JC; Mak D; Kantarjian H; Yang D; Ruvolo V; Borthakur G
    Leuk Lymphoma; 2010 May; 51(5):911-919. PubMed ID: 20423286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.
    Wang W; Qin JJ; Voruganti S; Wang MH; Sharma H; Patil S; Zhou J; Wang H; Mukhopadhyay D; Buolamwini JK; Zhang R
    Gastroenterology; 2014 Oct; 147(4):893-902.e2. PubMed ID: 25016295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles.
    Aguilar A; Sun W; Liu L; Lu J; McEachern D; Bernard D; Deschamps JR; Wang S
    J Med Chem; 2014 Dec; 57(24):10486-98. PubMed ID: 25496041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.
    Canon J; Osgood T; Olson SH; Saiki AY; Robertson R; Yu D; Eksterowicz J; Ye Q; Jin L; Chen A; Zhou J; Cordover D; Kaufman S; Kendall R; Oliner JD; Coxon A; Radinsky R
    Mol Cancer Ther; 2015 Mar; 14(3):649-58. PubMed ID: 25567130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.
    Wang S; Zhao Y; Aguilar A; Bernard D; Yang CY
    Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28270530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
    Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
    Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.